138 related articles for article (PubMed ID: 9731110)
1. A highly specific functional test for factor V leiden: A modified tissue factor assay for activated protein C resistance.
Arkel YS; Ku D; Kamiyama M; Pajaro R; Alder H; Marchand A
Haemostasis; 1997; 27(6):290-304. PubMed ID: 9731110
[TBL] [Abstract][Full Text] [Related]
2. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
Ragland BD; Reed CE; Eiland BM; Tichenor PH; Hudson CL; Fritsma GA; Adler BK; Marques MB
Am J Clin Pathol; 2003 Jan; 119(1):66-71. PubMed ID: 12520699
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance.
Liebman HA; Sutherland D; Bacon R; McGehee W
Br J Haematol; 1996 Dec; 95(3):550-3. PubMed ID: 8943900
[TBL] [Abstract][Full Text] [Related]
4. Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.
Galli M; Duca F; Ruggeri L; Finazzi G; Negri B; Moia M
Thromb Haemost; 1998 Aug; 80(2):246-9. PubMed ID: 9716147
[TBL] [Abstract][Full Text] [Related]
5. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Baig MA
Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
[TBL] [Abstract][Full Text] [Related]
7. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
[TBL] [Abstract][Full Text] [Related]
8. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
[TBL] [Abstract][Full Text] [Related]
9. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Viveros ME; Cabiedes J; Reyes E; Cabral AR
Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
[TBL] [Abstract][Full Text] [Related]
10. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
[TBL] [Abstract][Full Text] [Related]
11. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
12. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
De Bel AV; Van der Cruyssen GA; Devreese KM
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
[TBL] [Abstract][Full Text] [Related]
13. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
14. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
15. Lupus anticoagulant testing with optical end point automation.
Luddington R; Scales C; Baglin T
Thromb Res; 1999 Nov; 96(3):197-203. PubMed ID: 10588462
[TBL] [Abstract][Full Text] [Related]
16. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
Kraus M; Zander N; Fickenscher K
Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
[TBL] [Abstract][Full Text] [Related]
17. Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation.
de Ronde H; Bertina RM
Blood Coagul Fibrinolysis; 1999 Jan; 10(1):7-17. PubMed ID: 10070830
[TBL] [Abstract][Full Text] [Related]
18. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.
Aboud MR; Ma DD
Br J Haematol; 1997 Jun; 97(4):798-803. PubMed ID: 9217178
[TBL] [Abstract][Full Text] [Related]
19. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene.
Bokarewa MI; Bremme K; Falk G; Sten-Linder M; Egberg N; Blombäck M
Thromb Res; 1995 May; 78(3):193-200. PubMed ID: 7631299
[TBL] [Abstract][Full Text] [Related]
20. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
